[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-362745-105":59,"doc-detail-362745-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","neoadjuvant-fc-enhanced-anti-ctla-4-targets-tregs-to-augment-androgen-deprivation-in-high-risk-prostate-cancer-a-randomized-phase-i-trial","Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer - A randomized phase I trial","","High-risk localized prostate cancer often shows poor outcomes after surgery, and there remains no established role for neoadjuvant therapy. This phase I, single-center, two-arm, open-label randomized study evaluates afucosylated Fc-enhanced anti-CTLA-4 (BMS-986218) combined with presurgical androgen deprivation therapy (ADT) for safety, feasibility, and immunologic activity. Mechanistic analyses show reduced tumor regulatory T-cell frequencies linked to tumor macrophage Fc receptor signals, dendritic cell modulation, and enhanced T-cell priming, with biomarkers associated with improved responses.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/neoadjuvant-fc-enhanced-anti-ctla-4-targets-tregs-to-augment-androgen-deprivation-in-high-risk-prostate-cancer-a-randomized-phase-i-trial/362745/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/neoadjuvant-fc-enhanced-anti-ctla-4-targets-tregs-to-augment-androgen-deprivation-in-high-risk-prostate-cancer-a-randomized-phase-i-trial/362745.png","ImageObject",300,407,{"name":92,"@type":93},"Quinn Holloway","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What intervention does the phase I trial test in high-risk localized prostate cancer?","Question",{"text":112,"@type":113},"The trial tests an afucosylated Fc-enhanced anti-CTLA-4 antibody (BMS-986218) combined with presurgical androgen deprivation therapy (ADT).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the study designed and how many participants were randomized?",{"text":117,"@type":113},"It is a single-center, two-arm, open-label randomized study enrolling 24 men, comparing ADT with or without BMS-986218 before radical prostatectomy.",{"name":119,"@type":110,"acceptedAnswer":120},"Which immunological effects are reported after BMS-986218 treatment?",{"text":121,"@type":113},"BMS-986218 exposure associates with reduced tumor regulatory T-cell frequencies, implicates dendritic cell modulation, and augments T-cell priming; reductions in Tregs correlate with CD16a/FCGR3A on tumor macrophages.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},362745,1790217052,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336474466712,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Article  \nNeoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trial  \nGraphical abstract  \nHighlights  \n• Neoadjuvant ADT + Fc-enhanced αCTLA-4 is well tolerated  \nin localized prostate cancer  \nAuthors  \nCasey R. Ager, Aleksandar Obradovic, Patrick McCann,   , Charles G. Drake, Andrea Califano, Matthew C. Dallos  \nCorrespondence  \n[ager.casey@mayo.edu](ager.casey@mayo.edu) (C.R.A.),  \n[dallosm@mskcc.org](dallosm@mskcc.org) (M.C.D.)  \nIn brief  \nAger et al. investigate immunological effects of a next-generation Fc-enhanced αCTLA-4 antibody with hormonal therapy in a phase I neoadjuvant clinical trial in high-risk localized prostate cancer, leveraging single-cell multi-omics approaches. Their findings establish clinical feasibility, effects of Fc-enhanced αCTLA-4 on regulatory T cells, and putative response biomarkers.  \n• Fc-enhanced αCTLA-4 exposure associates with reduced tumor Treg frequencies  \n• Depth of Treg frequency reduction associates with response to Fc-enhanced αCTLA-4  \n• DC activation and T cell priming are implicated in response to Fc-enhanced αCTLA-4  \nAger et al., 2026, Cell Reports Medicine 7, 102638  \nMarch 17, 2026 © 2026 The Author(s) . Published by Elsevier Inc.  \n[https://doi.org/10.1016/j.xcrm.2026.102638](https://doi.org/10.1016/j.xcrm.2026.102638)  \nll  \nll  \nOPEN ACCESS  \nArticle  \nNeoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trial  \nCasey R. Ager,1,2,3,4,15,* Aleksandar Obradovic,5,15 Patrick McCann,6,10 Matthew Chaimowitz,2 Alexander L. E. Wang,5 Neha Shaikh,7 Parin Shah,7 Samuel S. Pan,7 Caroline J. Laplaca,8 Renu K. Virk,9 Jessica C. Hill,3 Collin Jugler,3 Grace DeFranco,3 Nilika Bhattacharya,3 Kade R. Copple,3 Phuong Nguyen,3 Howard I. Scher,10  \nGuarionex Joel DeCastro,8 Christopher B. Anderson,8 James M. McKiernan,8 Catherine S. Spina,6 Mark N. Stein,1 Karie Runcie,1 Charles G. Drake,1,8,16 Andrea Califano,5,7,11,12,13,14 and Matthew C. Dallos1,10,17,*  \n1Department of Medicine, Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, NY 10032, USA  \n2Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, NY 10032, USA  \n3Department of Immunology, Mayo Clinic Arizona, Phoenix, AZ 85054, USA  \n4Department of Urology, Mayo Clinic Arizona, Phoenix, AZ 85054, USA  \n5Department of Systems Biology, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY 10032, USA  \n6Department of Radiation Oncology, Columbia University Irving Medical Center, New York, NY 10032, USA  \n7Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY 10032, USA  \n8Department of Urology, Columbia University Irving Medical Center, New York, NY 10032, USA  \n9Department of Pathology, Columbia University Irving Medical Center, New York, NY 10032, USA  \n10Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA  \n11Department of Biochemistry & Molecular Biophysics, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY 10032, USA  \n12Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY 10032, USA  \n13Department of Biomedical Informatics, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY 10032, USA  \n14Chan Zuckerberg Biohub New York, New York, NY 10027, USA  \n15These authors contributed equally  \n16Present address: JnJ Innovative Medicine, Springhouse, PA 19002, USA  \n17Lead contact  \n*Correspondence: [ager.casey@mayo.edu](ager.casey@mayo.edu) (C. R.A.), [dallosm@mskcc.org](dallosm@mskcc.org) (M.C. D.) [https://doi.org/10.1016/j.xcrm.2026.102638](https://doi.org/10.1016/j.xcrm.20","cbCaiet6z5hNcBAK","https://ap.wps.com/l/cbCaiet6z5hNcBAK","pdf",8939174,26,"English","# Highlights\n## Summary\n# Introduction\n## Background on immune checkpoint blockade","[{\"question\":\"What intervention does the phase I trial test in high-risk localized prostate cancer?\",\"answer\":\"The trial tests an afucosylated Fc-enhanced anti-CTLA-4 antibody (BMS-986218) combined with presurgical androgen deprivation therapy (ADT).\"},{\"question\":\"How was the study designed and how many participants were randomized?\",\"answer\":\"It is a single-center, two-arm, open-label randomized study enrolling 24 men, comparing ADT with or without BMS-986218 before radical prostatectomy.\"},{\"question\":\"Which immunological effects are reported after BMS-986218 treatment?\",\"answer\":\"BMS-986218 exposure associates with reduced tumor regulatory T-cell frequencies, implicates dendritic cell modulation, and augments T-cell priming; reductions in Tregs correlate with CD16a/FCGR3A on tumor macrophages.\"}]","Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer - A randomized phase I trial | PDF",1790148992,66,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/582e2a7e006abe053ca63366fde6d6bd.webp",983,1276,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/945e1914eef206fb8658d23d1c6f526f.webp",982,1275,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/840a64a73d96ba0fecadbbfb9d2d52b2.webp",981,1273,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/88795615b7893f66e70d290caac176c1.webp",980,1272]